en en en en en en ru en en en fi en en en en en en en en en en en en en en fi es en en en en en en en en la en en en en jbo it en en en en en en pl en en en en ja en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en es en en en en pl
"Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infecti" by Yonghou Jiang, Fergal Duffy et al.
Jennifer J Hadlock, Institute for Systems Biology, Seattle, WA, USA.; Providence St. Joseph Health, Renton, Washington, United States of AmericaFollow
William Chour, Institute for Systems Biology, Seattle, Washington, United States of America
Venkata R Duvvuri, Institute for Systems Biology, Seattle, Washington, United States of AmericaFollow
Julie A Wallick, Providence St. Joseph Health, Renton, Washington, United States of America; Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, Washington, United States of AmericaFollow
Kim M Murray, Institute for Systems Biology, Seattle, Washington, United States of America
Henry G Kaplan, Swedish Cancer Institute, Swedish Medical Center, Seattle, Washington, United States of AmericaFollow
James R Heath, Institute for Systems Biology, Seattle, Washington, United States of America.
Jason D Goldman, Providence St. Joseph Health, Renton, Washington, United States of America.; Division of Infectious Diseases Swedish Medical Center Seattle WA.Follow
washington; seattle; isb; system; Adult; COVID-19; Graft Rejection; Humans; Kidney Transplantation; Male; Middle Aged; Receptor, Angiotensin, Type 1
BACKGROUND: Coronavirus disease 2019 (COVID-19) is associated with endothelial activation and coagulopathy, which may be related to pre-existing or infection-induced pro-thrombotic autoantibodies such as those targeting angiotensin II type I receptor (AT1R-Ab).
METHODS: We compared prevalence and levels of AT1R-Ab in COVID-19 cases with mild or severe disease to age and sex matched negative controls utilizing multivariate logistic and quantile regression adjusted for comorbidities including hypertension, diabetes, and heart disease.
RESULTS: There were trends toward increased prevalence (50% vs. 33%, p = 0.1) and level of AT1R-Ab (median 9.8 vs. 6.1 U/mL, p = 0.06) in all cases versus controls. When considered by COVID-19 disease severity, there was a trend toward increased prevalence of AT1R-Ab (55% vs. 31%, p = 0.07), as well as significantly higher AT1R-Ab levels (median 10.7 vs. 5.9 U/mL, p = 0.03) amongst individuals with mild COVID-19 versus matched controls. In contrast, the prevalence (42% vs. 37%, p = 0.9) and level (both medians 6.7 U/mL, p = 0.9) of AT1R-Ab amongst those with severe COVID-19 did not differ from matched controls.
CONCLUSIONS: These findings support an association between COVID-19 and AT1R-Ab, emphasizing that vascular pathology may be present in individuals with mild COVID-19 as well as those with severe disease.
Institute for Systems Biology
Jiang, Yonghou; Duffy, Fergal; Hadlock, Jennifer J; Raappana, Andrew; Styrchak, Sheila; Beck, Ingrid; Mast, Fred D; Miller, Leslie R; Chour, William; Houck, John; Armistead, Blair; Duvvuri, Venkata R; Yeung, Winnie; Haglund, Micaela; Wallner, Jackson; Wallick, Julie A; Hardy, Samantha; Oldroyd, Alyssa; Ko, Daisy; Gervassi, Ana; Murray, Kim M; Kaplan, Henry G; Aitchison, John D; Heath, James R; Sather, D Noah; Goldman, Jason D; Frenkel, Lisa; and Harrington, Whitney E, "Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection." (2021). Articles, Abstracts, and Reports. 5602.